Comparative Pharmacology
Head-to-head clinical analysis: SULFANILAMIDE versus SULMEPRIM PEDIATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFANILAMIDE versus SULMEPRIM PEDIATRIC.
SULFANILAMIDE vs SULMEPRIM PEDIATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydropteroic acid, thereby inhibiting bacterial folic acid synthesis.
Sulfamethoxazole inhibits bacterial dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits bacterial dihydrofolate reductase, blocking folate reduction; sequential blockade leads to bactericidal effect.
2-4 g orally initially, then 2-4 g every 4-6 hours, not to exceed 12 g/day; intravenous: 4-8 g/day in divided doses every 6-8 hours.
For Pneumocystis jirovecii pneumonia (PCP): 15-20 mg/kg/day (based on trimethoprim component) intravenously divided every 6-8 hours for 14-21 days. For other infections: 8-10 mg/kg/day (trimethoprim) orally or intravenously divided every 12 hours.
None Documented
None Documented
Clinical Note
moderateSulfanilamide + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Sulfanilamide."
Clinical Note
moderateSulfanilamide + Atorvastatin
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Atorvastatin."
Clinical Note
moderateSulfanilamide + Mecamylamine
"The risk or severity of adverse effects can be increased when Sulfanilamide is combined with Mecamylamine."
Clinical Note
moderateTerminal elimination half-life: 7-12 hours; prolonged in renal impairment (up to 24-48 hours).
Terminal elimination half-life: Sulfamethoxazole 9–12 hours, Trimethoprim 8–11 hours; prolonged in renal impairment (creatinine clearance <15 mL/min) requiring dose adjustment.
Primarily renal via glomerular filtration and tubular secretion; ~50-70% excreted unchanged in urine; biliary/fecal excretion minimal (<5%).
Renal excretion accounts for approximately 70% (as unchanged sulfamethoxazole and trimethoprim) and 20% as metabolites; biliary/fecal elimination is minor at <10%.
Category C
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic
Sulfanilamide + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Sulfanilamide."